Aralez Pharmaceuticals clinical trials
The registry lists 27 studies whose lead sponsor is Aralez Pharmaceuticals or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 18, 2016.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 27studies on the registry
- 0open to participants now
What it is testing
The drugs Aralez Pharmaceuticals’ studies test, most studies first; none is open now — 9 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 27 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 1008
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 7 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Aralez Pharmaceuticals.
Studies
Recruiting first, then most recently updated. Showing 27 of 27.
- A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated UlcersCompletedNCT00961350Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated UlcersCompletedNCT00960869Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric UlcersCompletedNCT00995410Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After BunionectomyCompletedNCT00293631Phase 2
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.CompletedNCT00293657Phase 2
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540CompletedNCT01557335Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With OsteoarthritisCompletedNCT00664560Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With OsteoarthritisCompletedNCT00665431Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) NaproxenCompletedNCT00527787Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) NaproxenCompletedNCT01129011Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to ArthrotecTerminatedNCT00594854Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)CompletedNCT00527904Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Phase I Study to Evaluate Bioavailability of Overencapsulated CelecoxibCompletedNCT00729495Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated AspirinCompletedNCT00441519Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With CelecoxibCompletedNCT00700687Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma LevelsCompletedNCT00749385Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Bioavailability of Naproxen 375 mg in Two FormulationsCompletedNCT00692055Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Effect of Food on the Bioavailability of PN400 ComponentsCompletedNCT00676442Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Bioavailability of Naproxen 500 mg in Three FormulationsCompletedNCT00665743Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- PK Study to Evaluate Esomeprazole Plasma Levels Following Administration of PN 400CompletedNCT00599404Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy VolunteersCompletedNCT00442208Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.CompletedNCT00367211Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy VolunteersCompletedNCT00632086Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated AspirinCompletedNCT00442052Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 MonthsCompletedNCT00442221Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine HeadachesCompletedNCT00433732Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane HeadachesCompletedNCT00434083Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals